Related Experiment Video
Updated: Sep 27, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Intensive Blood Pressure Treatment Goals: Evidence for Cardiovascular Protection From Observational Studies and
Paul K Whelton1,2, Joshua D Bundy1, Robert M Carey3
1Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Insights
Lowering systolic blood pressure (SBP) intensively reduces cardiovascular disease (CVD) events and mortality. Intensive SBP treatment benefits high-risk individuals, including older adults and those with diabetes or kidney disease.
Area of Science:
- Cardiology
- Public Health
- Gerontology
Background:
- Epidemiologic studies show a direct relationship between blood pressure (BP) and cardiovascular disease (CVD) events.
- Clinical trials indicate that intensive antihypertensive drug treatment is more effective in preventing CVD than less intensive approaches.
Approach:
- Meta-analyses of randomized controlled trials support intensive antihypertensive therapy, particularly for systolic blood pressure (SBP) targets of 130 mm Hg or even 120-124 mm Hg.
- The Systolic Blood Pressure Intervention Trial (SPRINT) compared intensive SBP goals (<120 mm Hg) with standard goals (<140 mm Hg) in high-risk individuals.
Key Points:
- Intensive SBP treatment (<120 mm Hg) significantly reduced CVD events and all-cause mortality in the SPRINT trial.
- Benefits were observed across subgroups, including older adults (≥65 years) and those with diabetes or chronic kidney disease.
- Intensive treatment also led to a lower incidence of cognitive impairment.
Conclusions:
- Current guidelines often recommend an SBP target of <130 mm Hg for high-risk adults.
- Intensive SBP management, potentially below 120 mm Hg, offers significant benefits for CVD prevention and mortality reduction in diverse high-risk populations.
Abstract:
Epidemiologic studies have consistently identified a strong, progressive relationship between blood pressure (BP) and cardiovascular disease (CVD) events, in a range of systolic BP (SBP) from as low as 90 mm Hg to as high as 180 mm Hg. Clinical trials have demonstrated greater prevention of CVD with more compared with less intensive antihypertensive drug treatment. Meta-analyses of randomized controlled trials provide strong evidence for more intensive antihypertensive drug therapy down to an SBP of 130 mm Hg, and to an SBP 120-124 mm Hg in the meta-analysis with the greatest statistical power. In the Systolic Blood Pressure Intervention Trial (SPRINT) randomization to an SBP treatment goal of <120 mm Hg compared with <140 mm Hg in persons with high CVD risk not only reduced the rate of CVD but also all-cause mortality. These benefits were noted in all of the prestated subgroups of interest, including those ≥65 years of age at baseline. In addition, cognitive impairment was less common in those randomized to the intensive compared with standard treatment. Most clinical practice guidelines recommend an SBP treatment target <130 mm Hg in adults with a high risk of CVD, which is the norm for many patients seen in clinical practice, especially those who are older, have diabetes mellitus, or chronic kidney disease.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Atherosclerosis III: Management
Hypertension II: Pathophysiology

